When restrictive cardiomyopathy occurs in the setting of haemochromatosis, identifying the iron-overload aetiology changes the clinical approach. This is a scenario where precise diagnosis unlocks a cause-specific, targeted intervention — rather than generic supportive management alone.

Clinical scenario: Restrictive cardiomyopathy in a patient with haemochromatosis. Recognition of haemochromatosis as the underlying aetiology is essential: it is a genetic phenocopy of restrictive cardiomyopathy with a specific, available treatment distinct from other causes.

Treatment approach — partial overview

Management in this setting centres on an iron-depletion procedure directed at the underlying cause. The complete protocol — including selection criteria, sequencing, monitoring parameters, and decision points — is available via the full structured regimen.

References

DOI: 10.1093/eurheartj/ehad194

Precise diagnosis is also essential for genetic phenocopies with available target treatments: ERT for Anderson–Fabry disease or glycogenosis such as Pompe disease; therapeutic phlebotomy for haemochromatosis; immunosuppressive therapeutics for sarcoidosis; new biological drugs for systemic diseases (e.g. autoimmune diseases with cardiac involvement that can reverse or stabilize by treating the disease itself); and removal of the toxic causes.

View source ↗

Treatment of Restrictive Cardiomyopathy in Haemochromatosis

Treatment approach — partial overview

References